BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Quarterly Earnings Results

BioCryst Pharmaceuticals (NASDAQ:BCRX) posted its earnings results on Wednesday. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04), FiscalAI reports. The business had revenue of $156.41 million for the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.The business’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.20 earnings per share.

Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:

• Strong commercial momentum: ORLADEYO net revenue was $148.3 million in Q1, with monthly new patient prescriptions slightly ahead of 2025 averages and early pediatric launch demand observed across all four pellet strengths.
• A manufacturing issue with ORLADEYO pediatric pellets will delay initial product fulfillment; the company says it does not expect the delay to change 2026 revenue guidance and will provide more timing details later this quarter.
• Development progress for navenibart is ahead of plan: ALPHA-ORBIT pivotal enrollment should complete by end of next month at ~145 patients, keeping a U.S. filing target by the end of 2027 and supporting a sizable injectable opportunity.
• Pipeline expansion: BCX17725 (KLK5 inhibitor) has started dosing in Part 4 of Phase I (up to 12 patients) with proof-of-concept data expected by year-end for Netherton syndrome.
• Mixed financial picture: GAAP was impacted by an in-process R&D charge of $698 million from the Astria asset acquisition, while non-GAAP results show strong operating profitability and pro forma liquidity of roughly $331 million after a $70 million upfront European license and a $400 million credit facility.

BioCryst Pharmaceuticals Stock Down 2.2%

Shares of NASDAQ:BCRX traded down $0.20 during midday trading on Wednesday, reaching $8.83. The company had a trading volume of 9,011,300 shares, compared to its average volume of 5,101,602. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.31. The stock has a market cap of $2.24 billion, a PE ratio of 7.36 and a beta of 0.57. The business’s 50 day moving average price is $9.05 and its 200 day moving average price is $7.81.

Analyst Upgrades and Downgrades

BCRX has been the topic of several recent analyst reports. Royal Bank Of Canada reduced their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Weiss Ratings upgraded BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Wednesday, March 4th. Needham & Company LLC cut their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Evercore initiated coverage on BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price objective for the company. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.10.

BioCryst Pharmaceuticals News Roundup

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Q1 sales and product performance beat estimates — BioCryst reported Q1 total revenue of ~$156.4M and ORLADEYO net revenue of $148.3M, up ~11% y/y (21% on a comparable basis excluding Europe), which supports top-line growth expectations. GlobeNewswire Q1 Release
• Positive Sentiment: Analyst support remains — Needham lowered its price target to $16 from $18 but kept a Buy rating, signaling continued bullish conviction despite trimming upside. Benzinga / TickerReport
• Neutral Sentiment: FY-2026 revenue guidance largely in-line — Management gave a revenue range of $635M–$660M, which brackets the consensus (~$648.7M); guidance reduces uncertainty on sales but contains no clear upside surprise. Company Slide Deck / Guidance
• Neutral Sentiment: Inducement RSU grants announced — BioCryst granted ~61,750 RSUs to six new hires under Nasdaq rules; typical for recruiting but a potential small source of future share-based dilution. GlobeNewswire RSU Notice
• Negative Sentiment: Reported EPS confusion / downside surprises weighed on sentiment — Some outlets flagged a large EPS miss (one report showed ($2.98) vs. ~$0.06 consensus), while others (Zacks) recorded a smaller loss (≈$0.03 vs. $0.06 estimate). The apparent discrepancy and an EPS miss drove selling pressure despite revenue strength. MarketBeat Earnings Note Zacks Q1 Summary

Insider Activity at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 150,000 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $9.15, for a total value of $1,372,500.00. Following the completion of the sale, the insider owned 400,703 shares of the company’s stock, valued at approximately $3,666,432.45. This represents a 27.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Focus Partners Wealth acquired a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at approximately $77,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of BioCryst Pharmaceuticals in the third quarter valued at approximately $81,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the third quarter valued at approximately $81,000. Cetera Investment Advisers lifted its position in shares of BioCryst Pharmaceuticals by 13.8% in the fourth quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 1,494 shares during the last quarter. Finally, Quantessence Capital LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $103,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.